Trial Profile
A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Osoresnontrine (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 05 Oct 2021 Results of initial findings assessing nonadherence data from two Phase 2 clinical trials studying the efficacy and safety of BI 409306 in people with Schizophrenia (NCT03351244) or Attenuated Psychosis Syndrome (NCT03230097) presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
- 30 Sep 2021 Status changed to discontinued. Reason the study was stopped was disruption due to COVID-19.
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.